European Neuropsychopharmacology
April 2019
Sabine Aust, Matti Gärtner, Laura Basso et al.
About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant. The N-methyl-d-aspartate (NMDA) glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in treatment-resistant MDD, but it is unknown whether its acute psychological effects are related to the later antidepressant...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
April 1, 2019
Fatemeh Khakpai, Mohaddeseh Ebrahimi-Ghiri, Sakineh Alijanpour et al.
The purpose of this study was to explore the possible interaction between ketamine and cannabinoid system in the modulation of depression-related responses using the forced swimming test (FST), tail suspension test (TST) and open-field test (OFT) in mice. Our results revealed that intra-peritoneal (i.p.) injection of ketamine (5 and 10 mg/kg), a non-competitive NMDA antagonist, dose-dependently...
The FASEB Journal
April 1, 2019
Meghan Hibicke, Alexus N. Landry, Zoe K. Talman et al.
7 citations
Introduction Psilocybin has recently demonstrated profound efficacy to alleviate depression and anxiety in several clinical trials and has received Breakthrough Status by the FDA. Symptomatic relief after only one or two therapeutic treatments last for at least several months in the vast majority of individuals. It is unclear whether the persistent antidepressant and anxiolytic effects are a...
Cutting Edge Psychiatry in Practice
March 31, 2019
James Stone
There has been considerable interest in the potential of ketamine as a novel antidepressant with a unique mechanism of action. In a number of small trials, ketamine has been shown to lead to reductions in depressive symptoms within hours of administration in patients with symptoms that are otherwise refractory to treatment, with the antidepressant response lasting for days. Although the...
American Journal of Psychiatry
March 29, 2019
J. Phillips, S. Norris, Jeanne Talbot et al.
416 citations
OBJECTIVE Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the antidepressant effects of a single ketamine infusion, a series of repeated ketamine infusions, and prolongation of response with maintenance...
Psychopharmacology
March 19, 2019
L. Sayson, Chrislean Jun Botanas, Raly James Perez Custodio et al.
RationaleDepressive syndrome or depression is a debilitating brain disorder affecting numerous people worldwide. Although readily available, current antidepressants have low remission rates and late onset times. Recently, N-methyl-D-aspartate (NMDA) receptor antagonists, like ketamine and methoxetamine (MXE), were found to elicit rapid antidepressant effects. As the search for...
Psychotherapy and Psychosomatics
March 18, 2019
Kurt Stocker, G. Hasler, Matthias Hartmann
5 “I kind of enjoyed the next few hours till dinner. I was still kind of floating on air” (5: 06) (T29). 6 “I had this awkward weight that I carried around me wherever I went (0: 47) ... Literally I had the sensation of this steal armor that I wore my entire life [that] – chunks of it – were falling off (3: 03)” (T16). 7 “I did immediately following the first session – and in the second and in...
Journal of Psychoactive Drugs
March 15, 2019
Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al.
207 citations
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as...
Proceedings of the National Academy of Sciences
March 13, 2019
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart et al.
153 citations
Significance Despite available medications for depression, currently approved antidepressants take months to exert therapeutic effects, and ∼30% of patients remain treatment resistant. In contrast, a single subanesthetic dose of ketamine exerts rapid (within hours) and sustained antidepressant actions. Preclinical studies indicate that the ketamine metabolite ( 2R , 6R )-hydroxynorketamine [(...
bioRxiv (Cold Spring Harbor Laboratory)
March 9, 2019
Andria Pelentritou, Levin Kuhlmann, John Cormack et al.
1 citation
preprint
B. Abstract Background. Despite their intriguing nature, investigations of the neurophysiology of N-methyl-D-aspartate (NMDA)-antagonists Xenon (Xe) and nitrous oxide (N 2 O) are limited and have revealed inconsistent frequency-dependent alterations, in spectral power and functional connectivity. Discrepancies are likely due to using low resolution electroencephalography restricted to sensor...
Journal of Neuroscience Research
March 2019
Ronald S. Duman, Matthew J. Girgenti
The neurobiology of fear memory and extinction has been the subject of extensive research efforts that have increased our understanding of the brain regions, circuitry, and the cellular and molecular determinants of fear memory processes. However, the inability to access and directly study the brains of PTSD patients has made it difficult to translate the rodent fear memory studies to...
Journal of Clinical Psychopharmacology
March 1, 2019
Kelly A. Bryant, Murat Altinay, Nora Finnegan et al.
Abstract Purpose There is an immediate need for more sustainable, effective therapies for treatment-resistant depression in patients who do not respond to traditional psychopharmacology. The aim of this study was to determine the efficacy and safety of intravenous ketamine infusions on the elderly population by using a case series of 6 geriatric patients with treatment-resistant depression....
Medical Hypotheses
March 1, 2019
Jahahreeh Finley
The neural correlates of consciousness and the mechanisms by which general anesthesia (GA) modulate such correlates to induce loss of consciousness (LOC) has been described as one of the biggest mysteries of modern medicine. Several cellular targets and neural circuits have been identified that play a critical role in LOC induced by GA, including the GABAA receptor and ascending arousal nuclei...
JAMA Psychiatry
March 1, 2019
Gihyun Yoon, Ismene L. Petrakis, John H. Krystal
152 citations
This study examines whether naltrexone pretreatment interferes with the antidepressant effects of ketamine.
Neuron
March 1, 2019
John H. Krystal, Chadi G. Abdallah, Gerard Sanacora et al.
443 citations
Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy. The rapid, profound, and sustainable antidepressant effects of ketamine...
Mental Health Weekly
February 25, 2019
Valerie A. Canady
A Food and Drug Administration (FDA) advisory committee earlier this month recommended the approval of a ketamine nasal spray treatment for adults with treatment‐resistant depression. Recent research has shown that ketamine treatment is gaining traction as an effective treatment for people struggling with depression.
Proceedings of the National Academy of Sciences
February 22, 2019
E. Lumsden, Timothy A. Troppoli, S. J. Myers et al.
159 citations
Significance Standard antidepressant treatments require weeks to show effectiveness. A single subanesthetic dose of ketamine rapidly attenuates many clinical signs and symptoms of depression; however, ketamine treatment also has many adverse effects, including dissociation and potential for abuse, which are mediated by NMDA glutamate receptor (NMDAR) inhibition. Previous work has revealed that...
Neuropsychopharmacology
February 6, 2019
Stjepan Curic, Gregor Leicht, Stephanie Thiebes et al.
Abnormal gamma-band oscillations (GBO) have been frequently associated with the pathophysiology of schizophrenia. GBO are modulated by glutamate, a neurotransmitter, which is continuously discussed to shape the complex symptom spectrum in schizophrenia. The current study examined the effects of ketamine, a glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist, on the auditory-evoked...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
February 2019
Richard E Rosch, Ryszard Auksztulewicz, Pui Duen Leung et al.
Disturbances in N-methyl-D-aspartate receptors (NMDARs)-as implicated in patients with schizophrenia-can cause regionally specific electrophysiological effects. Both animal models of NMDAR blockade and clinical studies in patients with schizophrenia have suggested that behavioral phenotypes are associated with reduction in inhibition within the frontal cortex. Here we investigate event-related...
Contemporary Clinical Trials
February 1, 2019
S. Mathew, S. Wilkinson, Murat Altinay et al.
54 citations
Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side effects. Ketamine has...